WELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears

Size: px
Start display at page:

Download "WELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears"

Transcription

1 Lab Talk: What a Lab Talk: What a Max Salfinger, MD, FIDSA, FAAM Executive Director, Advanced Diagnostic Laboratories Laboratory Director, Mycobacteriology & Pharmacokinetics National Jewish Health Lisa True RN, MS MDR Nurse Coordinator/Program Liaison TB Control Branch Center for Infectious Diseases California Department of Public Health Lana Kay Tyer RN, MS TB Nurse Consultant Washington Department of Health Laboratory slides curtesy of Julie Tans Kersten, TB Controller, Wisconsin and APHL Essentials for the Mycobacteriology Laboratory: Promoting Quality Practices 2 WELCOME 3 1

2 This is a talk about TB laboratory diagnostic tests!! 4 If you find lab reports confusing, raise your hand 5 If you already understand TB lab tests, you can leave 6 2

3 Just kidding, please stick around to help the rest of us! 7 We hope this will be fun and informative. And cover the objectives so you get your CEUs! 8 Objectives Understand laboratory tests available for the diagnosis of tuberculosis (TB) and antimicrobial susceptibility (AST) studies to assure the best patient outcomes. Have fun! Know who to ask when lab information doesn t make sense! 3

4 Day in the Life of TB Nurse Lab Report Patient 1-Positive Smear 11 Clinical Information Elderly woman US born History of COPD Admitted for shortness of breath 4

5 What a Nurse Thinks 13 Day in the Life of Microbiologist SMEAR MICROSCOPY

6 Smear Microscopy Procedure Smear: A small amount of primary patient specimen (direct or processed) is placed on a slide for the purpose of microscopic examination. The smear is stained by a special procedure to make AFB in the specimen more visible. Acid Fast Bacilli (AFB): resist decolorization with acid alcohol due to the lipid rich mycolic acids in the cell wall thereby retaining the primary stain Microscopic examination of the smears detects acid fast organisms such as Mycobacterium tuberculosis and nontuberculous mycobacteria (NTM) 16 AFB Smear Microscopy Auramine-O (fluorescent) Kinyoun or Ziehl-Neelsen (carbol fuchsin) 17 Reporting smear results Report an approximation of the number of AFB viewed on the slide using a semiquantitative scale Report smear results within 24 hours of specimen receipt Smear positive results are considered critical values and should be reported to the health care provider and public health department as soon as results are known

7 AFB Smear Microscopy Advantages and Limitations Advantage: Smear microscopy is a rapid, convenient and inexpensive test Limitations: Must be accompanied by additional testing including culture for confirmatory diagnosis Limited sensitivity High bacterial load 5,000 10,000 AFB /ml is required for detection Misses >45% of U.S. TB cases Microscopists should prepare and read a minimum of 15 smears per week to maintain technical proficiency 19 More Limitations of AFB Smear Microscopy Does not distinguish between viable and dead organisms Follow up specimens from patients on treatment may be smear positive yet culture negative Limited specificity All mycobacteria are acid fast (also Nocardia and others) Does not provide species identification Local prevalence of MTB and NTM determine the predictive values of a positive smear for MTB What a nurse hears 7

8 SPECIMEN COLLECTION 22 Specimen Quality is Important The results of tests, as they affect patient diagnosis and treatment, are directly related to the quality of the specimen collected and delivered to the laboratory. For initial diagnosis of TB: Collect a series of three sputum specimens, 8 24 hours apart, at least one of which is an early morning specimen* APHL: Essentials of the Mycobacteriology Laboratory: Promoting Quality Practices *Centers for Disease Control and Prevention. Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health Care Settings, MMWR 2005:54, RR Sputum Quality Specimens are thick and contain mucopurulent material from a deep cough. Ideally, 3 5 ml in volume, although smaller quantities are acceptable if the quality is satisfactory.* Poor quality specimens are thin and watery (unless induced). Saliva and nasal secretions are unacceptable. Check with your lab for specimen requirements. APHL: Essentials of the Mycobacteriology Laboratory: Promoting Quality Practices *Clinical and Laboratory Standards Institute. Laboratory detection and identification of mycobacteria; approved guideline. CLSI Document M48 A. Wayne, PA: CLSI;

9 NUCLEIC ACID AMPLIFICATION TESTING (NAAT) 25 Nucleic Acid Amplification Testing (NAAT) Use of molecular amplification techniques to detect MTBC DNA directly from the patient specimen Not a replacement for culture MTBC detected Sputum DNA extraction Amplification MTBC not detected 26 Nucleic Acid Amplification Testing (NAAT) Cepheid Xpert MTB/RIF (Sunnyvale, CA) Hologic Amplified MTD (San Diego, CA) Line Probe Assay Fujirebio Innogenetics INNO LiPA (Belgium/Sweden) HAIN Lifescience GenoType MTBC (Germany) Laboratory developed tests

10 Recommendation for Use of NAAT NAAT should be performed on at least one respiratory specimen from each patient with signs and symptoms of pulmonary TB for whom a diagnosis of TB is being considered but has not yet been established and for whom the test result would alter case management or TB control activities. Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis MMWR 2009; 58 (01); NAAT Limitations and Considerations Does not distinguish between live and dead organisms Not routinely used to differentiate between members of the TB complex Limited sensitivity for smear negative specimens Not indicated for use to determine bacteriologic cure or to monitor response to therapy 29 NAAT Limitations and Considerations Smear needed for interpretation of test results Culture is still the gold standard for TB diagnosis Culture is necessary for phenotypic antimicrobial susceptibility testing and genotyping

11 What a nurse hears Results from NAAT tests Two additional sputa collected Both were smear positive again GenXpert tests both negative for TB Tested for inhibitors, not present Patient released from airborne isolation No TB treatment, NTM identified on culture Lab Report Patient 2: Positive AFB Growth on Culture 11

12 Clinical Information 63 year old diabetic man from the Philippines Fall at home, CXR showed infiltrates Sputa x3, all were smear negative 4 weeks later there is a report of +AFB growth on culture What a nurse thinks? MYCOBACTERIAL CULTURE

13 Purpose of Mycobacterial Culture Detection of Mycobacterium tuberculosis complex (MTBC) The most clinically significant mycobacterial species for public health Isolation almost always signifies disease, except in the case of laboratory cross contamination MTBC organisms are not present in the environment Detection of Nontuberculous Mycobacteria (NTM) Are opportunistic pathogens in humans and may cause significant human disease Clinicians ultimately responsible for determining the importance of a NTM Almost all of these species can be found in environmental samples 37 Culture for Mycobacteria Detects viable mycobacteria from patient specimens Most sensitive and specific method for detecting mycobacteria ( Gold standard ) Slowest Method Average time to identification of TB from smear positive specimens= 12.8 days* Average time to identification of TB from smear negative specimens = 20.2 days* Range for detection of TB: 6 81 days* Laboratory will hold cultures 6 8 weeks before reporting as negative *Wisconsin State Laboratory of Hygiene, unpublished data 38 Mycobacterial Culture Use of culture increases the number of TB cases found by 30 50% over smear alone ~10 viable bacilli/ml of sputum needed for culture compared to at least 5,000 bacilli/ml of sputum for microscopy Culture used for species identification, antimicrobial susceptibility testing (AST), and genotyping Culture also used to monitor patient response to treatment

14 Culture for Mycobacteria at WSLH Type of Media Incubation Broth In automated instrument Detects bacterial growth Incubated for 42 days before reported as negative BD BACTEC TM MGIT TM Solid Plate or tube Visually inspected for colony growth 40 IDENTIFICATION OF MYCOBACTERIAL SPECIES 41 Identification of Mycobacterial Species Once a culture is growing, assays must be performed to identify the organisms Most laboratories use a multifaceted approach that includes: Phenotypic characteristics: The observable physical or biochemical characteristics of an organism Genotypic characteristics: the genetic makeup of an organism

15 Analysis Mycobacteria Culture Identification Methods Method DNA Proteins Cell wall mycolic acids Enzymes AccuProbes, Line probe assays, PCR, DNA sequencing Matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI TOF MS) High performance liquid chromatography (HPLC) Biochemical Reactions 43 Clinical Significance of MTBC and NTM Identification of MTBC is the most important finding in the laboratory and has serious clinical and public health consequences While some NTM can cause disease, not all NTM isolation is clinically significant Accurate and timely identification of mycobacteria is crucial Use a multi-faceted approach that includes a rapid identification and phenotypic assessment before issuing a final report 44 Culture Identification Results Isolated: Significance M. tuberculosis, M. bovis, M. bovis BCG, M. caprae, M. microti, M. africanum, M. canettii, M. pinnipedii, and M. mungi M. avium complex, M. gordonae, M. kansasii, M. simiae, M. terrae complex, M. xenopi M. abscessus & its subspecies, M. chelonae, M. fortuitum, M. mucogenicum M. tuberculosis complex (MTBC) Nontuberculous mycobacteria (NTM): slow growers Nontuberculous mycobacteria (NTM): rapid growers

16 Culture Results 46 What Nurse Thinks Lab Report Patient 3: Positive Xpert MTB/Rifampin 16

17 Clinical Information 59 yo healthy male from Ukraine No history of previous TB disease or treatment Mild cough and fever CXR cavitation in left upper lobe Sputum smear positive x3 What a Nurse Thinks MOLECULAR DETECTION OF DRUG RESISTANCE

18 Molecular Detection of Drug Resistance For rapid prediction of multi drug resistant and extensively drug resistant TB Molecular detection of mutations that confer resistance to TB drugs Molecular results should be correlated with culture based results, if possible 52 Interpreting GenXpert Results Not all rpob mutations result in rifampin resistance Send isolate for additional testing Sequencing can characterize the mutation and determine whether it is a clinically significant mutation (rule out silent mutations) If the rpob mutation confers resistance, likely MDR TB Drug Rifampin INH Ethambutol PZA Kanamycin Amikacin Capreomycin Fluoroquinolone Molecular Detection of Drug Resistance Genes Sequenced rpob inha, katg embb pnca rrs, eis rrs rrs, tlya gyra 18

19 CDC MDDR Results 55 CDC MDDR Results Locus Result Interpretation rpob (RRDR) No mutation Probably rifampin susceptible. (97% of RMP R isolates in our inhouse evaluation of 550 clinical isolates have a mutation at this locus.) 56 CDC MDDR Results Locus Result Interpretation katg (Ser315 codon) Mutation: AGC>ACC Ser315Thr Isoniazid Resistant (100% of isolates in our in house evaluation of 550 clinical isolates with this mutation are INH R)

20 CULTURE BASED DRUG SUSCEPTIBILITY TESTING 58 Culture-based Drug Susceptibility Testing (DST) Predicts in vivo success or failure of chemotherapy agents Guides choice of drugs provides the best chance of cure Offers insight into appropriate treatment for contacts of patients with active TB Molecular results should be correlated with culturebased results, if possible 59 Susceptibility Testing of M. tuberculosis complex isolates Drugs Tested Turn Around Time (after pure isolate obtained) TB First Line Drugs (BD MGIT ) isoniazid (INH) 0.2 ug/ml isoniazid (INH) 1.0 ug/ml rifampin 1.0 ug/ml ethambutol 5.0 ug/ml pyrazinamide 100 ug/ml 7 20 days 3 weeks TB Second Line Drugs capreomycin (10ug/ml) ethionamide (5 ug/ml) kanamycin (6 ug/ml) ofloxacin 2 ug/ml) PAS (2 ug/ml) rifabutin (0.5 ug/ml) streptomycin 2 ug/ml) streptomycin (10 ug/ml)

21 Challenges with Culture-based AST Drug Limitations Reference Rifampin false susceptibility may be of concern in commercial broth systems Williamson IJTLD :216 Van Deun et al. JCM 2013; 51(8): Ethambutol false susceptibility may be of concern in commercial broth systems PZA false resistance may be of concern in commercial broth systems Yakus et al., Tuberc Res Treat. 2016; Epub 2016 Jun 8 Chedore, et al JCM 48: Recommended Turnaround Time for TB First-line AST Initial isolates of MTBC should be tested against a panel of first line drugs using a rapid commercial broth system CDC recommends that AST results should ideally be available to the submitter within 17 days of identification of MTBC 62 Culture-based AST Report

22 CDC Culture-based AST Report 64 What a nurse hears Resources Centers for Disease Control and Prevention. Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health Care Settings, MMWR 2005:54, RR 17 Clinical and Laboratory Standards Institute. Laboratory detection and identification of mycobacteria; approved guideline. CLSI Document M48 A. Wayne, PA: CLSI; Essentials for the Mycobacteriology Laboratory: Promoting Quality Practices: Core Curriculum/Pages/default.aspx Drug Resistant Tuberculosis A Survival Guide for Clinicians, 3 rd edition, Curry International Tuberculosis Center

23 Questions?

Ken Jost, BA, has the following disclosures to make:

Ken Jost, BA, has the following disclosures to make: Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict

More information

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing 1. Essentials for the Mycobacteriology Laboratory: Promoting Quality Practices 1.1 Overview: Mycobacterial Culture, Identification,

More information

Stacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona

Stacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona Role of the Laboratory in TB Diagnosis Stacy White, PhD May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Stacy White, PhD has the following disclosures

More information

WSLH Testing and Surveillance Updates

WSLH Testing and Surveillance Updates WSLH Testing and Surveillance Updates Wisconsin Mycobacteriology Laboratory Network annual conference November 4, 2015, Madison, WI Updates Outline Collection and Transport Smear and Culture Nucleic Acid

More information

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014 TB Nurse Case Management San Antonio, Texas April 1 3, 2014 Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant

More information

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive San Antonio, Texas November 11 14, 2014 TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant

More information

Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013

Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013 TB Nurse Case Management San Antonio, Texas April 9-11, 2013 Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013 Ken Jost has the following disclosures to make: No conflict of interests No relevant

More information

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012 TB Nurse Case Management San Antonio, Texas March 7-9, 2012 Diagnosis of TB: Laboratory Ken Jost Wednesday March 7, 2012 Ken Jost has the following disclosures to make: No conflict of interests No relevant

More information

TB 101 Disease, Clinical Assessment and Lab Testing

TB 101 Disease, Clinical Assessment and Lab Testing TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain

More information

The ABC s of AFB s Laboratory Testing for Tuberculosis. Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory

The ABC s of AFB s Laboratory Testing for Tuberculosis. Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory The ABC s of AFB s Laboratory Testing for Tuberculosis Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory Laboratory TAT Goals Case Study Specimen Collection Testing Contact

More information

CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service

CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service Beverly Metchock, DrPH, D(ABMM) Team Lead, Reference Laboratory

More information

TB Laboratory for Nurses

TB Laboratory for Nurses TB Laboratory for Nurses Shea Rabley, RN, MN Consultant Mayo Clinic Center for Tuberculosis 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Participants will be able to: 1. Name 2 safety

More information

Diagnosis and Management of Active Tuberculosis

Diagnosis and Management of Active Tuberculosis Diagnosis and Management of Active Tuberculosis Zelalem Temesgen, MD FIDSA AAHIVS 2013 MFMER slide-1 Disclosures None 2013 MFMER slide-2 Objectives By the end of this session, participants should be able

More information

MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex

MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex Marie Claire Rowlinson, PhD D(ABMM) Florida Bureau of Public Health Laboratories

More information

Laboratory Diagnosis and Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex. Objectives

Laboratory Diagnosis and Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex. Objectives Laboratory Diagnosis and Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex Marie-Claire Rowlinson, PhD D(ABMM) Calin Chiribau, PhD, MT(ASCP) Florida Bureau of Public Health Laboratories

More information

Objectives. TB Laboratory Methods

Objectives. TB Laboratory Methods TB Laboratory Methods Beverly Metchock, Dr.P.H., D(ABMM) Team Leader, Reference Laboratory, Mycobacteriology Laboratory Branch February 2011 Objectives General overview of mycobacteriology (TB) lab practices

More information

CDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California

CDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California CDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California These guidelines are intended to be used as an educational aid to help clinicians make informed decisions about patient

More information

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Mycobacteria Diagnostic Testing in Manitoba Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Acknowlegements: Assunta Rendina: Charge Tech HSC Lab Joyce Wolf & Dr. Meenu Sharma: NML Dr. Kanchana

More information

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS The Laboratory s Role in Caring for Patients Diagnosed with TB Frances Morgan, PhD October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE

More information

Laboratory Diagnosis for MDR TB

Laboratory Diagnosis for MDR TB Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe

More information

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility

More information

TB is Local. Barry Chin, Boston Globe, 10/15/2008. * BUT only in appropriate setting

TB is Local. Barry Chin, Boston Globe, 10/15/2008. * BUT only in appropriate setting Diagnosis of Tuberculosis 2012 New Tools, Tricks, Thinking? John Bernardo, M.D. Pulmonary Section, Boston University School of Medicine Massachusetts Department of Public Health Objectives To review the

More information

Diagnosis of drug resistant TB

Diagnosis of drug resistant TB Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million

More information

TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai

TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%

More information

Receipt within 1 day of specimen collection. Report AFB b smear result within 1 day from receipt of specimen

Receipt within 1 day of specimen collection. Report AFB b smear result within 1 day from receipt of specimen Recommendation Promote rapid delivery of specimens to the laboratory Use fluorescent acid-fast staining and promptly transmit results by phone, FAX, or electronically Identify growth as acid-fast and use

More information

Frances Jamieson, MD and Kevin May, BSc November 15 th,

Frances Jamieson, MD and Kevin May, BSc November 15 th, Frances Jamieson, MD and Kevin May, BSc November 15 th, 2016 1 TB Elimination: Back To Basics Financial Interest Disclosure (over the past 24 months) Dr. Frances amieson Company Speaker Advisory Research

More information

Rapid Diagnostic Techniques for Identifying Tuberculosis Ken Jost November 13, 2008

Rapid Diagnostic Techniques for Identifying Tuberculosis Ken Jost November 13, 2008 Tuberculosis Updates for Clinicians San Antonio, Texas November 13, 2008 Rapid Diagnostic Techniques for Identifying Tuberculosis Ken Jost November 13, 2008 Rapid Diagnostic Techniques for Identifying

More information

Public Health Mycobacteriology (TB) Laboratory Testing Services

Public Health Mycobacteriology (TB) Laboratory Testing Services Public Health Mycobacteriology (TB) Laboratory Testing Services Gary Budnick Supervising Microbiologist Connecticut Department of Public Health Laboratory Branch Hartford, Connecticut Specimen Collection

More information

Communication between clinician and laboratory Molecular detection of M. tuberculosis complex

Communication between clinician and laboratory Molecular detection of M. tuberculosis complex 3 Laboratory 3rd edition contributors: PENNAN M. BARRY, MD, MPH & SHOU-YEAN GRACE LIN, MS General information on TB laboratory work..................... 32 Molecular methods for detection of M. tuberculosis

More information

Nucleic Acid Amplification Testing for the Diagnosis of TB

Nucleic Acid Amplification Testing for the Diagnosis of TB Roche Nucleic Acid Amplification Testing for the Diagnosis of TB David Warshauer, PhD Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene 19 th /20 th Century Traditional Algorithm

More information

Principles of laboratory diagnosis of M. tuberculosis. Anne-Marie Demers, MD, FRCPC 11 September 2017

Principles of laboratory diagnosis of M. tuberculosis. Anne-Marie Demers, MD, FRCPC 11 September 2017 Principles of laboratory diagnosis of M. tuberculosis Anne-Marie Demers, MD, FRCPC 11 September 2017 QUESTION Which statement is false? 1) A smear can only be on a concentrated specimen 2) It is normal

More information

AFB Identification Texas Approach

AFB Identification Texas Approach AFB Identification Texas Approach Ken Jost Texas Department of State Health Services 6th National Conference on Laboratory Aspects of TB June 21, 2010 DSHS-Austin TB Lab Customers & Samples Year 2009 175

More information

Mycobacterial cell wall. Cell Cycle Lengths. Outline of Laboratory Methods. Laboratory Methods

Mycobacterial cell wall. Cell Cycle Lengths. Outline of Laboratory Methods. Laboratory Methods Laboratory Methods Cell Cycle Lengths Generation time (hrs) Days needed for 26 generations (colony) E. coli 0.33 0.36 Nancy Connell, PhD Professor, nfectious Disease Department of Medicine Center for Emerging

More information

Why are We Concerned with Non-Tuberculous Mycobacteria?

Why are We Concerned with Non-Tuberculous Mycobacteria? Why are We Concerned with Non-Tuberculous Mycobacteria? Wisconsin State Laboratory of Hygiene Julie Tans-Kersten, MS, BS-MT (ASCP) Tuberculosis Laboratory Program Coordinator Wisconsin State Laboratory

More information

NTM Plus Case Studies

NTM Plus Case Studies NTM Plus Case Studies Youngmi Kim, Sr. Microbiologist MS, M(ASCP) Case 1 Referred Culture for ID & appropriate susceptibility Case 1 7/7/15: MGIT broth received DOC: 5-30-15 Source: FNA Mesenteric Mass,

More information

TB Updates for the Physician Rochester, Minnesota June 19, 2009

TB Updates for the Physician Rochester, Minnesota June 19, 2009 TB Updates for the Physician Rochester, Minnesota June 19, 2009 Mycobacterial Laboratory Science Update Nancy L. Wengenack, Ph.D. Associate Professor of Laboratory Medicine and Pathology Division of Clinical

More information

TB Laboratory Services

TB Laboratory Services TB Laboratory Services Max Salfinger, MD, FIDSA,FAAM Co-Lead, DrPH Laboratory Concentration University of South Florida, College of Public Health max@health.usf.edu http://health.usf.edu/publichealth/

More information

Update on MALDI-TOF Validation

Update on MALDI-TOF Validation Update on MALDI-TOF Validation Donald Busalacchi B.S. Microbiologist- WSLH WMLN 2015 Review Matrix-Assisted Laser Desorption Ionization Time-of- Flight A form of Mass Spectroscopy utilizing a soft ionization

More information

Case Study: TB-HIV co-infection

Case Study: TB-HIV co-infection Case Study: TB-HIV co-infection Julia Greenleaf, RN, MPH Public Health Nurse Public Health Madison & Dane County With guest appearance by Julie Tans-Kersten, MS, BSMT (ASCP) Director, WI TB Program 33

More information

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection? Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:

More information

The Clinical Impact of Rapid Nucleic Acid Amplification Tests for Detection of M. tuberculosis

The Clinical Impact of Rapid Nucleic Acid Amplification Tests for Detection of M. tuberculosis The Clinical Impact of Rapid Nucleic Acid Amplification Tests for Detection of M. tuberculosis DR. PHYLLIS DELLA-LATTA, D(ABMM), FAAM DIRECTOR, CLINICAL MICROBIOLOGY SERVICE PROFESSOR, CLINICAL PATHOLOGY

More information

Guidelines for Tuberculosis Control in New Zealand 2010 Chapter 11: Mycobacteriology: Laboratory Methods and Standards

Guidelines for Tuberculosis Control in New Zealand 2010 Chapter 11: Mycobacteriology: Laboratory Methods and Standards Guidelines for Tuberculosis Control in New Zealand 2010 Chapter 11: Mycobacteriology: Laboratory Methods and Standards Ministry of Health. 2010. Guidelines for Tuberculosis Control in New Zealand 2010.

More information

Nucleic Acid Amplification Test for Tuberculosis. Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services

Nucleic Acid Amplification Test for Tuberculosis. Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services Nucleic Acid Amplification Test for Tuberculosis Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services What is this test? Nucleic Acid Amplification Test (NAAT)

More information

Role of the Laboratory in TB Diagnosis and Management

Role of the Laboratory in TB Diagnosis and Management Role of the Laboratory in TB Diagnosis and Management Michael Pentella, Ph.D., D(ABMM), CIC Associate Director University Hygienic Lab Clinical Associate Professor, College of Public Health, University

More information

NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL

NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL Susan Novak-Weekley, S(M), ASCP, Ph.D., D(ABMM) Director of Microbiology,

More information

NEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM

NEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM Crosswalk of Proposed Revision to Standards Any standards not addressed here remain in effect. (changes are underlined) Practice 8 (TB S8): Smears Only Permit Category - Specimen Submission and Result

More information

A Clinician s Guide to the TB Laboratory

A Clinician s Guide to the TB Laboratory A Clinician s Guide to the TB Laboratory EXCELLENCE EXPERTISE INNOVATION Dear Healthcare Professional, This book provides basic information on the use of the public health and clinical laboratories in

More information

MYCOBACTERIOLOGY INTRODUCTION RANGE OF LABORATORY SERVICES

MYCOBACTERIOLOGY INTRODUCTION RANGE OF LABORATORY SERVICES MYCOBACTERIOLOGY INTRODUCTION The Central Tuberculosis Laboratory (CTBL) of the Department of Pathology provides laboratory diagnosis of tuberculosis (TB) and other mycobacterial diseases for all hospitals,

More information

Characteristics of Mycobacterium

Characteristics of Mycobacterium Mycobacterium Characteristics of Mycobacterium Very thin, rod shape. Culture: Aerobic, need high levels of oxygen to grow. Very slow in grow compared to other bacteria (colonies may be visible in up to

More information

PCR and direct amplification for tuberculosis diagnosis. Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital,

PCR and direct amplification for tuberculosis diagnosis. Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital, PCR and direct amplification for tuberculosis diagnosis Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital, Paris, France Educational Workshop 05- ECCMID 2015 Copenhagen

More information

Use of the Cepheid GeneXpert to Release Patients from Airborne Isolation

Use of the Cepheid GeneXpert to Release Patients from Airborne Isolation Use of the Cepheid GeneXpert to Release Patients from Airborne Isolation Dave Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene WISCONSIN STATE LABORATORY

More information

Essential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective

Essential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective Essential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective James Watt, MD, MPH Acting Chief, Tuberculosis Control Branch California Department of Public

More information

LABORATORY METHODS: TUBERCULOSIS DIAGNOSIS

LABORATORY METHODS: TUBERCULOSIS DIAGNOSIS TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE LABORATORY METHODS: TUBERCULOSIS DIAGNOSIS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe three laboratory

More information

General Session IV - Dale Schwab April 20, 2017

General Session IV - Dale Schwab April 20, 2017 The Culture of Clinical Commercial Labs Presented by: Dale Schwab PhD, Senior Scientific Director, Infectious Disease April 20, 2017 Objectives Challenges for the reference laboratory in MTB diagnosis/opportunities

More information

Laboratory Diagnostic Techniques. Hugo Donaldson Consultant Microbiologist Imperial College Healthcare NHS Trust

Laboratory Diagnostic Techniques. Hugo Donaldson Consultant Microbiologist Imperial College Healthcare NHS Trust Laboratory Diagnostic Techniques Hugo Donaldson Consultant Microbiologist Imperial College Healthcare NHS Trust Learning Objectives 1) When to consider a diagnosis of TB 2) When to consider a referral

More information

Chapter 4 Diagnosis of Tuberculosis Disease

Chapter 4 Diagnosis of Tuberculosis Disease Chapter 4 Diagnosis of Tuberculosis Disease Table of Contents Chapter Objectives.... 75 Introduction.... 77 Medical Evaluation.......................................................... 78 Chapter Summary...

More information

Laboratory s Role in the Battle Against Drug Resistant Tuberculosis

Laboratory s Role in the Battle Against Drug Resistant Tuberculosis Laboratory s Role in the Battle Against Drug Resistant Tuberculosis Angela M. Starks, Ph.D. Chief, Laboratory Branch Division of Tuberculosis Elimination June 6, 2016 National Center for HIV/AIDS, Viral

More information

Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis

Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis Grace Lin, MS. Research Scientist grace.lin@cdph.ca.gov APHL 8 th TB Lab Conference San Diego 8-19-13 Harmonizing? There

More information

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)

More information

TB BASICS: PRIORITIES AND CLASSIFICATIONS

TB BASICS: PRIORITIES AND CLASSIFICATIONS TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE NOVEMBER 1-4, 2016 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1.

More information

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No

More information

EDUCATIONAL COMMENTARY TUBERCULOSIS PART II: DIAGNOSTIC TESTING FOR THE DETECTION AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS

EDUCATIONAL COMMENTARY TUBERCULOSIS PART II: DIAGNOSTIC TESTING FOR THE DETECTION AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS DETECTION AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE

More information

CHAPTER 3: DEFINITION OF TERMS

CHAPTER 3: DEFINITION OF TERMS CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria

More information

DNA sequencing for the confirmation of rifampin resistance detected by Cepheid Xpert

DNA sequencing for the confirmation of rifampin resistance detected by Cepheid Xpert JCM Accepted Manuscript Posted Online 4 March 2015 J. Clin. Microbiol. doi:10.1128/jcm.03433-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 DNA sequencing for the confirmation

More information

National TB Services Survey Report

National TB Services Survey Report National TB Services Survey Report APHL Report Diagnosing TB JUNE 2012 The Association of Public Health Laboratories (APHL) is a national non-profit organization dedicated to working with members to strengthen

More information

Molecular assays in Tuberculosis. Jatin Yegurla Junior resident

Molecular assays in Tuberculosis. Jatin Yegurla Junior resident Molecular assays in Tuberculosis Jatin Yegurla Junior resident 17-3-2018 Contents Introduction TB-PCR Line Probe assay (LPA) GenoType MTBDRsl test (Second line LPA) Xpert MTB/RIF (GeneXpert) (CB-NAAT)

More information

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Appendix B Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Since publication of the Recommendations for Counting Reported Tuberculosis Cases 1 in January 1977, numerous changes

More information

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Appendix B Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Since publication of the Recommendations for Counting Reported Tuberculosis Cases 1 in January 1977, numerous changes

More information

THE ROLE OF THE LABORATORY

THE ROLE OF THE LABORATORY TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE NOVEMBER 1-4, 2016 THE ROLE OF THE LABORATORY LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe three

More information

THE ROLE OF THE LABORATORY

THE ROLE OF THE LABORATORY TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE THE ROLE OF THE LABORATORY LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe three laboratory methods

More information

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Managing Complex TB Cases Diana M. Nilsen, MD, RN Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private

More information

Laboratory services for the diagnosis and management of TB, MDR-TB, XDR-TB in HIV co-infected patients

Laboratory services for the diagnosis and management of TB, MDR-TB, XDR-TB in HIV co-infected patients Laboratory services for the diagnosis and management of TB, MDR-TB, XDR-TB in HIV co-infected patients Max Salfinger Fogarty Workshop on TB/HIV Cali, Colombia - March 28, 2007 John E. Fogarty Bricklayer;

More information

Treatment of TB. David Griffith, MD May 12, TB for Community Providers. Phoenix, Arizona

Treatment of TB. David Griffith, MD May 12, TB for Community Providers. Phoenix, Arizona Treatment of TB David Griffith, MD May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION David Griffith, MD has the following disclosures to make: No conflict

More information

Case Study 2016 Wisconsin Mycobacteriology Laboratory Network Annual Conference November 17, 2016

Case Study 2016 Wisconsin Mycobacteriology Laboratory Network Annual Conference November 17, 2016 Case Study 2016 Wisconsin Mycobacteriology Laboratory Network Annual Conference November 17, 2016 Raymond P. Podzorski, Ph.D, D(ABMM) St. Mary s Hospital Laboratory and Wisconsin Region SSMHealth 608-258-6393

More information

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How

More information

TUBERCULOSIS. Pathogenesis and Transmission

TUBERCULOSIS. Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are

More information

Transmission and Pathogenesis of Tuberculosis. Transmission and Pathogenesis of Tuberculosis. Mycobacteria. Introduction to the pathogen Transmission

Transmission and Pathogenesis of Tuberculosis. Transmission and Pathogenesis of Tuberculosis. Mycobacteria. Introduction to the pathogen Transmission Transmission and Pathogenesis of Tuberculosis Adithya Cattamanchi MD, MAS Assistant Professor of Medicine University of California San Francisco Slides adapted from James Watts, Phil Hopewell Transmission

More information

Transmission and Pathogenesis of Tuberculosis

Transmission and Pathogenesis of Tuberculosis Transmission and Pathogenesis of Tuberculosis Adithya Cattamanchi MD, MAS Associate Professor of Medicine University of California San Francisco Slides adapted from James Watts, Phil Hopewell Transmission

More information

Tuberculosis Tools: A Clinical Update

Tuberculosis Tools: A Clinical Update Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary

More information

Diagnosis of tuberculosis

Diagnosis of tuberculosis Diagnosis of tuberculosis Madhukar Pai, MD, PhD Assistant Professor, Epidemiology McGill University, Montreal, Canada madhukar.pai@mcgill.ca Global TB Case Detection A major concern 2.6 million new smear

More information

Case presentation. Dr Connie Haley, MD, MPH Dr Gautam Kalyatanda, MD

Case presentation. Dr Connie Haley, MD, MPH Dr Gautam Kalyatanda, MD Case presentation Dr Connie Haley, MD, MPH Dr Gautam Kalyatanda, MD History of presenting illness 20 Year old woman from Nigeria who came to study at Montgomery in August 2013 About 2 weeks after arriving,

More information

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries

More information

A retrospective evaluation study of diagnostic accuracy of Xpert MTB/RIF assay, used for detection of Mycobacterium tuberculosis in Greece

A retrospective evaluation study of diagnostic accuracy of Xpert MTB/RIF assay, used for detection of Mycobacterium tuberculosis in Greece Örebro University School of Health and Medical Science Biomedical Laboratory Science Programme 180 credits Degree project in biomedical laboratory science, advanced course, 15 credits May 21, 2015 A retrospective

More information

Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.

Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis. Title Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium. Author(s) Ho, PL; Yam, WC; Leung, CC; Yew, WW; Mok, TYW; Chan, KS; Tam, CM Citation Hong Kong Medical

More information

Communicable Disease Control Manual Chapter 4: Tuberculosis

Communicable Disease Control Manual Chapter 4: Tuberculosis Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from

More information

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis Amit S. Chitnis, MD, MPH; Pennan M. Barry, MD, MPH; Jennifer M. Flood, MD, MPH. California Tuberculosis Controllers

More information

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening

More information

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012 TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release

More information

Experts on Xpert: A laboratorian and a clinician discuss interpretation of Xpert MTB/RIF Results

Experts on Xpert: A laboratorian and a clinician discuss interpretation of Xpert MTB/RIF Results Experts on Xpert: A laboratorian and a clinician discuss interpretation of Xpert MTB/RIF Results Pennan Barry, MD, MPH Grace Lin, MS September 6, 08 Curry International Tuberculosis Center Learning Objectives

More information

Comparison of the Xpert MTB/RIF Assay and Real-time PCR for the Detection of Mycobacterium tuberculosis

Comparison of the Xpert MTB/RIF Assay and Real-time PCR for the Detection of Mycobacterium tuberculosis Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 45, no. 3, 2015 327 Comparison of the Xpert MTB/RIF Assay and Real-time PCR for the Detection of Mycobacterium tuberculosis

More information

TB Nurse Case Management Davenport, Iowa September 27 28, 2011

TB Nurse Case Management Davenport, Iowa September 27 28, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Role of the Laboratory in the TB Diagnosis and Management Michael Pentella, PhD, MS, SM(ASCP), CIC, D(ABMM) September 27, 2011 Michael Pentella,

More information

Evaluation of Genxpert Real Time PCR POC in the Diagnosis of Multidrug Resistant TB Among Patients Attending NTBLTC Saye-Zaria Nigeria

Evaluation of Genxpert Real Time PCR POC in the Diagnosis of Multidrug Resistant TB Among Patients Attending NTBLTC Saye-Zaria Nigeria RESEARCH ARTICLE Open Access Journal of Infectious Diseases and Pathogenesis ISSN 577-7939 Evaluation of Genxpert Real Time PCR POC in the Diagnosis of Multidrug Resistant TB Among Patients Attending NTBLTC

More information

Shah: Discordant Growth- Molecular Rifampin Resistance 2/27/16 RELAPSED FAILED

Shah: Discordant Growth- Molecular Rifampin Resistance 2/27/16 RELAPSED FAILED /7/6 Discordant Growth- Molecular Diagnos7c Challenges and Treatment Outcomes Neha Shah, MD MPH Centers for Disease Control and Preven7on California Department of Health Tuberculosis Control NAR February

More information

MYCOBACTERIOLOGY SERVICE MANUAL

MYCOBACTERIOLOGY SERVICE MANUAL MYCOBACTERIOLOGY SERVICE MANUAL The Office of Laboratory Services (OLS) provides primary isolation and identification of Mycobacterium species in human diagnostic specimens. Reference specimens of AFB

More information

Received 4 June 2013; Final revision 1 August 2013; Accepted 30 August 2013; first published online 27 September 2013

Received 4 June 2013; Final revision 1 August 2013; Accepted 30 August 2013; first published online 27 September 2013 Epidemiol. Infect. (2014), 142, 1328 1333. Cambridge University Press 2013 doi:10.1017/s0950268813002409 SHORT REPORT Characterization of multi-drug resistant Mycobacterium tuberculosis from immigrants

More information

M.kansasii M.marinum M.avium M.simiae M.szulgai M.gordonae M.xenopi M.intermedium M.intracellulare M.scrofulaceum M.avium sp.

M.kansasii M.marinum M.avium M.simiae M.szulgai M.gordonae M.xenopi M.intermedium M.intracellulare M.scrofulaceum M.avium sp. Molecular-genetic methods for species identification of mycobacteria Smirnova T.G., Chernousova L.N., Vorobyeva A.V., Larionova E.E., Andreevskaya S.N. Central TB Research Institute of RAMS, Moscow 2010

More information

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis

More information

Treatment of Active Tuberculosis

Treatment of Active Tuberculosis Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest

More information

TB the basics. (Dr) Margaret (DHA) and John (INZ)

TB the basics. (Dr) Margaret (DHA) and John (INZ) TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2

More information